ATE103291T1 - Spezifische liganden fuer oestrogen- und progestagen-steroidhomonrezeptoren, deren verwendung und synthesezwischenprodukte. - Google Patents

Spezifische liganden fuer oestrogen- und progestagen-steroidhomonrezeptoren, deren verwendung und synthesezwischenprodukte.

Info

Publication number: ATE103291T1
Authority: AT; Austria
Prior art keywords: progestagen; ligands; receptors; steroid; homon
Prior art date: 1988-10-19

Application number

AT89402862T

Other languages

English (en)

Inventor

Marc Zeicher

Jacques Quivy

Original Assignee

Wallone Region

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-10-19

Filing date

1989-10-17

Publication date

1994-04-15

1989-10-17 Application filed by Wallone Region filed Critical Wallone Region

1994-04-15 Application granted granted Critical

1994-04-15 Publication of ATE103291T1 publication Critical patent/ATE103291T1/de

Links

239000003446 ligand Substances 0.000 title abstract 5
239000000262 estrogen Substances 0.000 title abstract 2
239000000583 progesterone congener Substances 0.000 title abstract 2
-1 PROGESTAGEN STEROID Chemical class 0.000 title 1
239000013067 intermediate product Substances 0.000 title 1
206010028980 Neoplasm Diseases 0.000 abstract 2
201000011510 cancer Diseases 0.000 abstract 2
WAHQVRCNDCHDIB-QZYSPNBYSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-acetyloxy-6,10,13-trimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] 3-cyclopentylpropanoate Chemical compound O([C@@H]1C=C2C(C)=C[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(OC(=O)C)C(C)=O)C(=O)CCC1CCCC1 WAHQVRCNDCHDIB-QZYSPNBYSA-N 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
229940011871 estrogen Drugs 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
108091008039 hormone receptors Proteins 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
150000002576 ketones Chemical group 0.000 abstract 1
230000002285 radioactive effect Effects 0.000 abstract 1
238000001959 radiotherapy Methods 0.000 abstract 1
108020003113 steroid hormone receptors Proteins 0.000 abstract 1
102000005969 steroid hormone receptors Human genes 0.000 abstract 1
238000002626 targeted therapy Methods 0.000 abstract 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/008—Ketals at position 17
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0081—Substituted in position 17 alfa and 17 beta
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)

AT89402862T 1988-10-19 1989-10-17 Spezifische liganden fuer oestrogen- und progestagen-steroidhomonrezeptoren, deren verwendung und synthesezwischenprodukte. ATE103291T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR8813737A FR2637803B1 (fr)	1988-10-19	1988-10-19	Ligands specifiques de recepteurs d'hormones steroides estrogenes et progestagenes, application et produits intermediaires de synthese
EP89402862A EP0365421B1 (de)	1988-10-19	1989-10-17	Spezifische Liganden für Östrogen- und Progestagen-Steroidhomonrezeptoren, deren Verwendung und Synthesezwischenprodukte

Publications (1)

Publication Number	Publication Date
ATE103291T1 true ATE103291T1 (de)	1994-04-15

Family

ID=9371153

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT89402862T ATE103291T1 (de)	1988-10-19	1989-10-17	Spezifische liganden fuer oestrogen- und progestagen-steroidhomonrezeptoren, deren verwendung und synthesezwischenprodukte.

Country Status (7)

Country	Link
US (1)	US5002753A (de)
EP (1)	EP0365421B1 (de)
JP (1)	JP2779011B2 (de)
AT (1)	ATE103291T1 (de)
CA (1)	CA2000979C (de)
DE (1)	DE68914087T2 (de)
FR (1)	FR2637803B1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2613937B1 (fr) *	1987-04-17	1989-07-21	Ire Celltarg Sa	Ligands specifiques de recepteurs d'hormones steroides utiles pour la therapie ciblee ou l'imagerie medicale notamment du cancer
CN1041829C (zh) *	1993-06-28	1999-01-27	中国人民军事医学科学院放射医学研究所	17α-乙炔雌三醇-3-环戊醚的制备方法
US5427766A (en) *	1993-11-15	1995-06-27	The Dow Chemical Company	Radiolabeled steroids for use in radiochemical-guided surgery
US5922699A (en) *	1996-06-07	1999-07-13	Pherin Corporation	19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function
JP2010531638A (ja)	2007-06-12	2010-09-30	ケースウエスタンリザーブユニバーシティ	標的化された細胞死

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL7405626A (nl) *	1974-04-26	1975-10-28	Akzo Nv	Nieuwe 11-gesubstitueerde steroiden van de oestraanreeks.
JPS6051808A (ja) *	1983-08-31	1985-03-23	Sumitomo Electric Ind Ltd	光フアイバユニツト入り架空地線の接続部
DE3337179A1 (de) *	1983-10-10	1985-05-23	Schering AG, 1000 Berlin und 4709 Bergkamen	Estran- und androstan-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende praeparate
CA1259536A (en) *	1984-07-20	1989-09-19	Walter G. Lieberman	Rotary actuator
DE3427795A1 (de) *	1984-07-25	1986-02-06	Schering AG, 1000 Berlin und 4709 Bergkamen	Neue 17(alpha)-halogenvinyl-estran-derivate, ihre herstellung und verwendung in der medizin
FR2613937B1 (fr) *	1987-04-17	1989-07-21	Ire Celltarg Sa	Ligands specifiques de recepteurs d'hormones steroides utiles pour la therapie ciblee ou l'imagerie medicale notamment du cancer

1988
- 1988-10-19 FR FR8813737A patent/FR2637803B1/fr not_active Expired - Fee Related
1989
- 1989-10-17 AT AT89402862T patent/ATE103291T1/de active
- 1989-10-17 EP EP89402862A patent/EP0365421B1/de not_active Expired - Lifetime
- 1989-10-17 DE DE68914087T patent/DE68914087T2/de not_active Expired - Lifetime
- 1989-10-18 CA CA002000979A patent/CA2000979C/fr not_active Expired - Lifetime
- 1989-10-18 US US07/423,141 patent/US5002753A/en not_active Expired - Lifetime
- 1989-10-19 JP JP1272738A patent/JP2779011B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE68914087D1 (de)	1994-04-28
CA2000979C (fr)	2000-06-13
FR2637803A1 (fr)	1990-04-20
US5002753A (en)	1991-03-26
FR2637803B1 (fr)	1993-07-09
EP0365421B1 (de)	1994-03-23
JPH02174794A (ja)	1990-07-06
DE68914087T2 (de)	1994-09-08
CA2000979A1 (fr)	1990-04-19
JP2779011B2 (ja)	1998-07-23
EP0365421A1 (de)	1990-04-25

Similar Documents

Publication	Publication Date	Title
Miller et al.	1976	Oestradiol synthesis from C19 steroids by human breast cancers
Fisher et al.	1969	Cancer of the breast: size of neoplasm and prognosis
DE69126816T2 (de)	1998-02-12	Metallkomplexe, die Addukte von Säure und Dioximliganden enthalten, zur Markierung von Proteinen und anderen Amin enthaltenden Verbindungen
ATE85652T1 (de)	1993-02-15	Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung.
Hanson et al.	1984	Preparation and evaluation of 17α-[125I] iodovinyl-11β-methoxyestradiol as a highly selective radioligand for tissues containing estrogen receptors: concise communication
AU6198086A (en)	1987-03-05	Agents for use in tumour diagnosis, imaging, localization or treatment
ZIELINSKI et al.	1986	16 α-[125I] Iodo-11 β Methoxy-17 β-Estradiol: A Radiochemical Probe for Estrogen-Sensitive Tissues
ATE103291T1 (de)	1994-04-15	Spezifische liganden fuer oestrogen- und progestagen-steroidhomonrezeptoren, deren verwendung und synthesezwischenprodukte.
Bigott et al.	2005	Design and synthesis of functionalized cyclopentadienyl tricarbonylmetal complexes for technetium-94m PET imaging of estrogen receptors
FR2613937B1 (fr)	1989-07-21	Ligands specifiques de recepteurs d'hormones steroides utiles pour la therapie ciblee ou l'imagerie medicale notamment du cancer
Garin et al.	2004	Development and biodistribution of 188Re-SSS lipiodol following injection into the hepatic artery of healthy pigs
DaSilva et al.	1990	Synthesis and structure-affinity of a series of 7. alpha.-undecylestradiol derivatives: a potential vector for therapy and imaging of estrogen-receptor-positive cancers
Hunter et al.	2000	Single isomer technetium-99m tamoxifen conjugates
Sykes et al.	1995	Direct labeling of monoclonal antibodies with technetium-99m by photoactivation
DE69109515D1 (de)	1995-06-14	Neue 17-spiro substituierte Steroide, Verfahren zu deren Herstellung und Zwischenprodukten davon, ihre Verwendung als Arzneimittel sowie pharmazeutische Präparate davon.
LAMB et al.	1958	Sensitivity to fluorescent (blue-green) light
Middlebrooks et al.	2018	Acute inflammatory thyromegaly following checkpoint inhibition: A new imaging entity?
Ash et al.	1979	Biliary and faecal excretion of misonidazole in man
Adjogatse et al.	2024	170 Long term outcomes of the FiGaRO trial: 18F-FDG-PET in Guided Dose-Painting with Intensity Modulated Radiotherapy in Oropharyngeal Tumours
Pomper	1989	Fluorine-18-labeled estrogens, progestins and corticosteroids for receptor-based imaging of breast tumors and target areas of the brain
Delclos et al.	1977	Can the fletcher gamma ray colpostat system be extrapolated to other systems?
Hainfeld et al.	1994	Derivatized gold clusters and antibody-gold cluster conjugates
Reinstein et al.	1978	Portal film duplication using instant photography
Gopal et al.	1975	Feasibility studies of radiation sterilization of some pharmaceutical products
Quinn et al.	1987	Management of advanced gynecologic malignancies with dominant pelvic presentations